SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

7 marketing jobs

Mineralys Therapeutics logo
8 hrs ago

Vice President, Corporate Communications

Mineralys Therapeutics

USA (Remote)Full time$320K/yr – $335K/yr
Mineralys Therapeutics logo
6 days ago

Sr. Director, HCP Marketing

Mineralys Therapeutics

USA (Remote)Full time$245K/yr – $260K/yr
Mineralys Therapeutics logo
2 months ago

Director, Brand Communications

Mineralys Therapeutics

USA (Remote)Full time$185K/yr – $210K/yr
Mineralys Therapeutics logo
3 months ago

Director, HCP Marketing

Mineralys Therapeutics

USA (Remote)Full time$200K/yr – $220K/yr
Mineralys Therapeutics logo
3 months ago

Director, Patient Marketing

Mineralys Therapeutics

USA (Remote)Full time$200K/yr – $220K/yr
Mineralys Therapeutics logo
5 months ago

Marketing Coordinator

Mineralys Therapeutics

USA (Remote)Full time$80K/yr – $95K/yr
Mineralys Therapeutics logo
5 months ago

Senior Director, Global Marketing

Mineralys Therapeutics

USA (Remote)Full time$250K/yr – $265K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

7 jobs
Mineralys Therapeutics logo

Vice President, Corporate Communications

Mineralys Therapeutics

USA (Remote)

$320K/yr - $335K/yrIn-houseFull-timeSenior level15+ years exp.
8 hrs ago
Mineralys Therapeutics logo

Sr. Director, HCP Marketing

Mineralys Therapeutics

USA (Remote)

$245K/yr - $260K/yrIn-houseFull-timeSenior level10+ years exp.
6 days ago
Mineralys Therapeutics logo

Director, Brand Communications

Mineralys Therapeutics

USA (Remote)

$185K/yr - $210K/yrIn-houseFull-timeSenior level
2 months ago
Mineralys Therapeutics logo

Director, HCP Marketing

Mineralys Therapeutics

USA (Remote)

$200K/yr - $220K/yrIn-houseFull-timeDirector/executive8+ years exp.
3 months ago
Mineralys Therapeutics logo

Director, Patient Marketing

Mineralys Therapeutics

USA (Remote)

$200K/yr - $220K/yrIn-houseFull-timeDirector/executive8+ years exp.
3 months ago
Mineralys Therapeutics logo

Marketing Coordinator

Mineralys Therapeutics

USA (Remote)

$80K/yr - $95K/yrIn-houseFull-timeSenior level10+ years exp.
5 months ago
Mineralys Therapeutics logo

Senior Director, Global Marketing

Mineralys Therapeutics

USA (Remote)

$250K/yr - $265K/yrIn-houseFull-timeSenior level10+ years exp.
5 months ago
Mineralys Therapeutics logo
Mineralys Therapeutics

Vice President, Corporate Communications

USA (Remote)

$320K/yr – $335K/yrSenior Level15+ years expFull time

Posted 8 hrs ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own and execute Mineralys enterprise and product communications, shaping the corporate narrative, stakeholder engagement, and crisis readiness, while building and guiding internal and external functions, brand, and investor-aligned messaging.

  • Define and lead the corporate narrative across audiences and channels
  • Build and oversee internal and external communications capabilities
  • Drive crisis readiness, brand governance, and cross-functional collaboration

Job Description

Responsibilities

  • Own the enterprise communications strategy, spanning external and internal audiences, and align it to corporate objectives and launch readiness milestones.
  • Define the Mineralys corporate narrative and core messaging platform, and ensure it is applied consistently across every audience and channel.
  • Establish the communications operating model, including planning calendars, message review and approval pathways, spokesperson protocols, and escalation and crisis procedures.
  • Set measures of effectiveness for communications and report on outcomes to the Executive Team.
  • Oversee the creation of all external communications, including press releases, media statements and corporate messaging campaigns.
  • Build and manage relationships with key healthcare, trade, and financial media; serve as a company spokesperson and prepare and coach executives for media interactions.
  • Lead communications for all significant corporate milestones, including clinical data readouts, regulatory submissions and approvals, launch announcements, business development activity, and commercial progress.
  • Lead issues management and crisis communications, including preparedness planning, rapid response, and executive counsel under pressure.
  • Own the corporate brand: identity, visual standards, voice, and tone, and ensure disciplined application across all internal and external materials.
  • Partner with Commercial team to ensure the corporate brand and product brand reinforce one another while remaining appropriately distinct.

Requirements

  • 15+ years of progressive corporate communications experience, with substantial experience in the biotech or pharmaceutical sector.
  • Demonstrated track record of building a communications function, ideally as the first or sole senior communications leader in an organization.
  • Experience leading communications at a publicly traded company, ideally spanning development-stage through commercial-stage milestones.
  • Experience across the full product lifecycle, including clinical data disclosure, regulatory milestones, and product launch.
  • Familiarity with the biotech investor and healthcare media landscape.
  • Demonstrated internal communications and change communications capability in a fast-growing organization.
  • Proven issues and crisis management experience, including advising executives in high-stakes situations.
  • Exceptional written and verbal communication skills; a strategic storyteller who can translate complex scientific and financial information into clear, compelling narratives.
  • A player-coach who is comfortable operating without infrastructure and building it while delivering.
  • Strong cross-functional collaboration skills; track record of working closely with Finance, Legal, Clinical, Regulatory, Medical Affairs, and Commercial teams.

Preferred

  • Experience supporting a first commercial launch.
  • Experience building and evolving internal communications channels and governance as an organization scales.
Mineralys Therapeutics logo

Mineralys Therapeutics

5.0 Glassdoor

At Mineralys Therapeutics we aim to redefine hypertension diagnosis, management and treatment. We are driven to break the “trial and failure” approach to hypertension management and bring a personalized approach to the management of hypertension.

Founded in 2020
Wayne, Pennsylvania, USA
84 employees (3 in marketing)
www.mineralystx.com
0% recommend to a friend

Salaries

Posted range

$320K/yr – $335K/yr

Taken straight from the job posting.

See all Mineralys Therapeutics salaries

Marketing Team

Marketing Team Size
3 (4% of company)
Marketing Roles Posted (Last 30 Days)
2

Funding

Total Funding
$740.5M
Last Raise
$287.5M
Post IPO Equity, 7 months ago

Funding History

  • Sep 2025
    Post IPO Equity • $287.5M
  • Mar 2025
    Post IPO Equity • $175M
  • Feb 2024
    Post IPO Equity • $120M

Traffic Signals

Monthly Visitors
9.8K
Traffic Source Mix
Search
35.6%
Direct
44.3%
Referral
5.7%
Social
12.7%
Paid
1.5%

Headcount Trend

Current headcount: ~84

Recent News

Mineralys Therapeutics Insider Sold Shares Worth $43,350,000, According to a Recent SEC Filing
Nov 24, 2025 • MarketScreener
Director’s Major Stock Sale Shakes Up Mineralys Therapeutics!
Nov 22, 2025 • TipRanks
Catalys Pacific fund sells Mineralys Therapeutics shares for $43.35m
Nov 21, 2025 • Investing.com
What moving averages say about Mineralys Therapeutics Inc. - Trade Exit Report & Community Consensus Picks
Nov 19, 2025 • newser.com
MLYS Stock Price Dives 11% After Mixed Securities Filing
Nov 17, 2025 • StocksToTrade
Mineralys Therapeutics Shares Fall Following Executives' Stock Sale
Nov 14, 2025 • MarketScreener
Mineralys Therapeutics CEO Congleton sells $9 million in stock By Investing.com
Nov 14, 2025 • Investing.com Canada
Mineralys Therapeutics CEO Congleton sells $9 million in stock By Investing.com
Nov 14, 2025 • Investing.com Australia
Mineralys Therapeutics director Karydas sells $689k in shares
Nov 13, 2025 • Investing.com
Wells Fargo Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Nov 12, 2025 • The Globe and Mail
HC Wainwright & Co. Maintains Mineralys Therapeutics (MLYS) Buy Recommendation
Nov 12, 2025 • Nasdaq
Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook
Nov 11, 2025 • TipRanks
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Ins
Nov 11, 2025 • GuruFocus
Mineralys Therapeutics Q3 2025 Earnings Call Transcript
Nov 10, 2025 • MarketBeat
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q3 Loss $0.52, vs. FactSet Est of $0.61 Loss
Nov 10, 2025 • MarketScreener
Mineralys Therapeutics Reports Q3 2025 Financial Results
Nov 10, 2025 • TipRanks
Mineralys Therapeutics stock hits all-time high at 44.8 USD
Nov 10, 2025 • Investing.com
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 10, 2025 • Yahoo Finance
Mineralys (Nasdaq: MLYS) plans NDA by Q1 2026; Explore-OSA enrollment complete
Nov 10, 2025 • Stock Titan
Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans
Nov 8, 2025 • Yahoo Finance
Mineralys (NASDAQ: MLYS) posts 7.5 mmHg BP, 25.6% UACR reductions at ASN Kidney Week
Nov 7, 2025 • Stock Titan
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Nov 5, 2025 • Yahoo Finance
Mineralys (NASDAQ: MLYS) plans fireside chats at Guggenheim, Stifel, Evercore Nov–Dec 2025
Nov 5, 2025 • Stock Titan
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
Nov 3, 2025 • Yahoo Finance
HC Wainwright & Co. Maintains Mineralys Therapeutics (MLYS) Buy Recommendation
Oct 30, 2025 • Nasdaq
Visualizing Mineralys Therapeutics Inc. stock with heatmaps - July 2025 Earnings & Weekly Top Gainers Trade List
Oct 24, 2025 • newser.com
Real time scanner hits for Mineralys Therapeutics Inc. explained - 2025 Momentum Check & Fast Moving Stock Trade Plans
Oct 24, 2025 • newser.com
Has Mineralys Therapeutics Inc. found a price floor - July 2025 EndofMonth & Safe Entry Trade Reports
Oct 24, 2025 • newser.com
Real time scanner hits for Mineralys Therapeutics Inc. explained - July 2025 PreEarnings & Real-Time Buy Zone Alerts
Oct 23, 2025 • newser.com
Lorundrostat’s High-Profile Clinical Data Spotlight Could Be a Game Changer for Mineralys Therapeutics (MLYS)
Oct 22, 2025 • Sahm
Will Mineralys Therapeutics Inc. stock maintain growth story - Share Buyback & Consistent Return Strategy Ideas
Oct 21, 2025 • newser.com
Understanding Mineralys Therapeutics Inc.’s price movement - Global Markets & High Conviction Trade Alerts
Oct 21, 2025 • newser.com
Mineralys (NASDAQ: MLYS) Launch-HTN Phase 3 in ASN Kidney Week 2025 Best of JAMA & NEJM
Oct 21, 2025 • Stock Titan
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
Oct 21, 2025 • GlobeNewswire
Mineralys Therapeutics Reaches Analyst Target Price
Oct 21, 2025 • Nasdaq
Tools to assess Mineralys Therapeutics Inc.’s risk profile - Weekly Profit Report & Smart Money Movement Tracker
Oct 21, 2025 • newser.com
Real time breakdown of Mineralys Therapeutics Inc. stock performance - July 2025 Intraday Action & Community Consensus Trade Alerts
Oct 21, 2025 • newser.com
A Look at Mineralys Therapeutics's Valuation as Phase 2 EXPLORE-OSA Trial Reaches Enrollment Milestone
Oct 12, 2025 • Sahm
Mineralys Therapeutics (MLYS) Is Up 10.8% After Completing Phase 2 OSA Trial Enrollment – What's Changed
Oct 11, 2025 • Sahm
Why Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension Trial
Oct 3, 2025 • Yahoo Finance
Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions (MLYS)
Oct 1, 2025 • Seeking Alpha
Sleep Apnea Breakthrough: Mineralys's Novel Drug Trial Targets Nighttime Blood Pressure Control
Sep 30, 2025 • Stock Titan
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
Sep 30, 2025 • GlobeNewswire
Mineralys completes enrollment in phase 2 sleep apnea drug trial
Sep 30, 2025 • Investing.com
Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups
Sep 30, 2025 • Insider Monkey
Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups
Sep 30, 2025 • Yahoo Finance
Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock: Should You Buy?
Sep 29, 2025 • Yahoo Finance
Mineralys Therapeutics stock hits all-time high at 39.23 USD
Sep 18, 2025 • Investing.com
Did New Phase 3 Results and FDA Milestones Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?
Sep 17, 2025 • Yahoo Finance
Mineralys Therapeutics chief medical officer sells $409k in shares
Sep 16, 2025 • Investing.com
Assessing Mineralys Therapeutics After Its 155% Surge and Strong Pipeline Developments
Sep 15, 2025 • simplywall.st
Mineralys Therapeutics Stock (MLYS) Opinions on $175M Public Offering and Clinical Trial Results
Sep 9, 2025 • Quiver Quantitative
A&O Shearman advises on Mineralys Therapeutics’ upsized USD287.5 million follow-on equity offering
Sep 9, 2025 • A&O Shearman
What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?
Sep 9, 2025 • Yahoo Finance
Major Investment Alert: Mineralys Therapeutics Sees Huge Stock Purchase!
Sep 8, 2025 • TipRanks
Ra Capital Healthcare Fund buys Mineralys Therapeutics shares for $30m
Sep 8, 2025 • Investing.com
16.9mmHg Blood Pressure Reduction: Mineralys' New Drug Shows Promise for Hard-to-Treat Hypertension Patients
Sep 5, 2025 • Stock Titan
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
Sep 5, 2025 • GlobeNewswire
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sep 4, 2025 • GlobeNewswire
$287.5M Raised: Hypertension Drug Developer Mineralys Completes Major Public Offering for Clinical Trials
Sep 4, 2025 • Stock Titan
Mineralys Therapeutics Closes $287.5 Million Public Offering to Support Clinical Development of Lorundrostat
Sep 4, 2025 • Quiver Quantitative
Mineralys Therapeutics closes $287.5 million public offering
Sep 4, 2025 • Investing.com
Stocks Showing Market Leadership: Mineralys Therapeutics Earns 98 RS Rating
Sep 3, 2025 • Investor's Business Daily
Jefferies raises Mineralys Therapeutics stock price target to $26 from $15
Sep 3, 2025 • Investing.com
Mineralys: Soaring As Rival's Hypertension Data Falls Short - Buy The Next Dip (MLYS)
Sep 3, 2025 • Seeking Alpha
Mineralys Therapeutics Announces Upsized Public Offering of Common Stock Raising Approximately $250 Million
Sep 3, 2025 • Quiver Quantitative
Mineralys Therapeutics Announces Public Offering of Shares
Sep 3, 2025 • TipRanks
Latham Advises Mineralys Therapeutics on Upsized US$250 Million Underwritten Public Offering of Common Stock
Sep 3, 2025 • Latham & Watkins LLP
Mineralys Therapeutics announces pricing of upsized $250.0 million underwritten public offering of common stock
Sep 3, 2025 • MarketScreener
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
Sep 3, 2025 • Mineralys Therapeutics, Inc.
Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug
Sep 2, 2025 • MSN
Q&A with Jon Congleton, CEO of Mineralys Therapeutics
Sep 2, 2025 • The Pharma Letter
Mineralys Therapeutics launches $175 million public stock offering
Sep 2, 2025 • Investing.com
Mineralys Therapeutics Halts Common Stock Offering
Sep 2, 2025 • TipRanks
Mineralys Therapeutics Shows Rising Price Performance With Jump To 85 RS Rating
Sep 2, 2025 • Investor's Business Daily
Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug
Sep 2, 2025 • Seeking Alpha
$250 Million Stock Offering: Hypertension Drug Developer Mineralys Prices Upsized Public Share Sale
Sep 2, 2025 • Stock Titan
Mineralys Therapeutics Prices Upsized Public Offering Of 9.80 Mln At $25.50/shr
Sep 2, 2025 • Nasdaq
Mineralys Therapeutics Jumps On Baxdrostat Hypertension Trial Results
Sep 2, 2025 • RTTNews
Mineralys Therapeutics announces proposed public offering of common stock
Sep 2, 2025 • MarketScreener
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
Sep 2, 2025 • Morningstar.com
Nasdaq Down 1%; Signet Jewelers Earnings Top Views
Sep 2, 2025 • Benzinga.com
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
Sep 2, 2025 • Mineralys Therapeutics, Inc.
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
Sep 2, 2025 • BioSpace
Mineralys Therapeutics Inc - Suspends Prospectus Supplement For ATM Equity Offering - SEC Filing
Sep 2, 2025 • Reuters
Buy Rating for Mineralys Therapeutics Driven by Competitive Position and Strategic Milestones
Sep 1, 2025 • TipRanks
ESC: 'Landmark' study backs AZ's baxdrostat for hypertension
Sep 1, 2025 • pharmaphorum
Mineralys Therapeutics, Inc. Earnings Call Highlights
Aug 31, 2025 • TipRanks
AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout
Aug 30, 2025 • Citeline News & Insights
Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade
Aug 18, 2025 • Yahoo Finance
Mineralys' Hypertension Drug Shows Promise in Multiple Studies, Heads Toward FDA Filing
Aug 12, 2025 • Stock Titan
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 12, 2025 • Mineralys Therapeutics, Inc.
H.C. Wainwright reiterates Buy rating on Mineralys stock, citing lorundrostat potential
Aug 9, 2025 • Investing.com Nigeria
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
Aug 4, 2025 • Mineralys Therapeutics, Inc.
Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect?
Jul 25, 2025 • Yahoo Finance
Astrazeneca’s baxdrostat solid in phase III hypertension trial
Jul 14, 2025 • BioWorld Financial Watch
Here's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
Jul 2, 2025 • Yahoo Finance
Mineralys reports positive phase 3 results for hypertension drug
Jun 30, 2025 • Investing.com
Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat
Jun 30, 2025 • Yahoo Finance
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
Jun 30, 2025 • GlobeNewswire

Links

www.mineralystx.comLinkedInX (Twitter)Crunchbase